Watch TNXP. Know when insiders buy.
One email the day a filing lands. Free.
TNXP
Tonix Pharmaceuticals Holding Corp.
5.43
−0.35 −6.06%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
69
PASS · insiders 62, shorts 75
Insiders, 90 days
+$40K
net buying · 2 buys, 0 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $93.1MP/E —DIV YIELD —FCF YIELD -169.77%REV TTM $29.1M +196.0%NET INCOME −$159.7MNET CASH $167.6M52W 5.43 – 20.35SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $13.5M | +577.9% | 94.8% | −$42.5M | −$40.6M | — | -2.44 | −$42.2M | $587K | −$42.8M | Aug 10 |
| Q1 2026 · Mar 31 | $6.9M | +183.2% | 77.1% | −$41.5M | −$40.2M | — | -2.93 | −$42.3M | $1.7M | −$44M | Aug 10 |
| Q4 2025 · Dec 31derived | $5.4M | +108.8% | 80.4% | −$48.3M | −$46.9M | — | -4.15 | −$39.6M | $1.9M | −$41.5M | Mar 12 |
| Q3 2025 · Sep 30 | $3.3M | +16.6% | 58.4% | −$33.1M | −$32M | — | -3.59 | −$28.8M | $962K | −$29.7M | Nov 10 |
| Q2 2025 · Jun 30 | $2M | −9.5% | -63.8% | −$28.3M | −$28.3M | — | -3.86 | −$14.8M | $527K | −$15.4M | Aug 10 |
| Q1 2025 · Mar 31 | $2.4M | −2.1% | 61.2% | −$16.1M | −$16.8M | — | -2.84 | −$16.6M | $6K | −$16.6M | Aug 10 |
| Q4 2024 · Dec 31derived | $2.6M | −31.7% | 54.2% | −$22.5M | −$22.1M | — | 289.57 | −$14.6M | $3K | −$14.6M | Mar 12 |
| Q3 2024 · Sep 30 | $2.8M | −29.3% | 44.9% | −$15.6M | −$14.2M | — | -22.68 | −$18.8M | $9K | −$18.8M | Nov 10 |
| Q2 2024 · Jun 30 | $2.2M | — | -52.5% | −$77.3M | −$78.8M | — | -1920.85 | −$9.9M | $0 | −$9.9M | Nov 10 |
| Q1 2024 · Mar 31 | $2.5M | — | 33.1% | −$21.4M | −$14.9M | — | -535.72 | −$17.6M | $108K | −$17.7M | Nov 10 |
| Q4 2023 · Dec 31derived | $3.8M | — | 37.4% | −$27.3M | −$27.3M | — | -14576.78 | −$22.3M | $438K | −$22.8M | Mar 18 |
| Q3 2023 · Sep 30 | $4M | — | 40.5% | −$28.1M | −$28M | — | -38.63 | −$23.4M | $1.8M | −$25.2M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $13.1M | 49.3% | −$125.7M | −$124M | -946.2% | -14.57 | −$99.8M | $3.4M | −$103.2M | $13.8M | — |
| FY2024 · to Dec 31 | $10.1M | 23.1% | −$136.7M | −$130M | -1288.3% | -176.60 | −$60.9M | $120K | −$61M | — | — |
| FY2023 · to Dec 31 | $7.8M | 39.0% | −$118.4M | −$116.7M | -1501.8% | -14720.25 | −$102M | $7.9M | −$109.9M | $14M | — |
| FY2022 · to Dec 31 | — | — | −$112.1M | −$110.2M | — | -20.01 | −$98.1M | $48.1M | −$146.2M | — | — |
| FY2021 · to Dec 31 | — | — | −$92.3M | −$92.3M | — | -8.10 | −$75.6M | $35.3M | −$110.9M | — | — |
| FY2020 · to Dec 31 | — | — | −$50.5M | −$50.5M | — | -0.55 | −$48.6M | $8.6M | −$57.1M | — | — |
Every number comes from Tonix Pharmaceuticals Holding Corp.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.